Results 121 to 130 of about 41,581 (185)

A Comprehensive, Updated Review of Ezetimibe: Evidence-Based Clinical Use for Atherosclerotic Cardiovascular Disease. [PDF]

Am J Cardiovasc Drugs
Liu HH, Liu ZH, Chen SS, Zhu CG, Li JJ.
europepmc   +1 more source

High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study. [PDF]

Ann Med
Ma J, Chen H, Guo C, He G, Yang G.
europepmc   +1 more source

Short-term effect of rosuvastatin versus atorvastatin on the corrected QT interval: a target trial emulation. [PDF]

Eur J Clin Pharmacol
Chen X, Liu Y, Wei W, Xia X, Wu X, Lu X, Hu G, Lu S, Shen Y.   +8 more
europepmc   +1 more source

Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial. [PDF]

Front Cardiovasc Med
Schäfer A, Großhennig A, Theis L, Schindler C, Grahl E, Stichtenoth DO, König T, Geller WA, Schmidt HHJG, Bavendiek U, Bauersachs J.   +10 more
europepmc   +1 more source

A hierarchical risk assessment framework for head-to-head comparison of statin safety profiles in Chinese patients. [PDF]

Sci Rep
Tsui L, Wang D, Fan C, Shi C.
europepmc   +1 more source

Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components. [PDF]

Clin Pharmacol Drug Dev
Lee S, Khwarg J, Bae S, Park DM, Park H, Lee S, Yu KS.   +6 more
europepmc   +1 more source

Comparative pharmacokinetics of a candesartan/amlodipine/atorvastatin fixed-dose combination 8 mg/5 mg/10 mg versus separate tablets in healthy subjects: a partial replicated crossover study. [PDF]

Transl Clin Pharmacol
Kim SY, Kwak YG, Kim MG, Moon SJ.
europepmc   +1 more source

Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial. [PDF]

Sci Rep
Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM.   +3 more
europepmc   +1 more source

Mechanistic insights into atorvastatin-induced hepatotoxicity: molecular pathways, clinical relevance, and strategies for safer personalized therapy. [PDF]

Clin Exp Med
Abdel-Rasol MA, El-Sayed WM.
europepmc   +1 more source

Coenzyme Q10 protects against atorvastatin-induced hepatotoxicity via attenuation of oxidative stress and functional modulation of CYP3A1. [PDF]

BMC Pharmacol Toxicol
Abdel-Rasol MA, Anwar MS, Taha HA, El-Sayed WM, AbdelRaouf K.   +4 more
europepmc   +1 more source